Abstract
Background: Leishmaniasis is a neglected disease that affects 15 million people around the world. Many limitations are associated to the treatment as high cost and toxicity. Several classes of natural substances with proven leishmanicidal activity were reported in the literature. Phytochemsitry study of Anaxagorea dolichocarpa (Annonacea) reported the isolation of aporphine alkaloids.
Methods: In this study, we evaluate the potential activity of the azaphenanthrene alkaloids eupolaramine, imbiline 1, imbiline 4, sampangine, 3-metoxisampangine and 4- metoxisampangine, isolated from A. dolichocarpa, together with a homemade databank of 142 aporphynic alkaloids isolated from Annonaceae, through ligand-based and structurebased virtual screening (VS) against Leishmania donovani. A diverse set selected from CHEMBL databank of 1397 structures, with tested antileishmanial activity against promastigote L. donovani, were classified according pIC50 values in order to generate and validate Random Forest model that show higher statistical indices values. The structure of six different L. donovani enzymes were downloaded from PDB databank and alkaloids structures were submitted to molecular docking.
Results: From the six azaphenanthrene alkaloids, sampangine, 3-methoxy, and 4-methoxy were indicated as potential actives by the RF model. Docking results gave similar values for all six azaphenanthrene alkaloids. So, we performed in vitro tests with sampangine, imbiline 1, imbiline 4, and eupolaramine, which are available in our laboratory, and that show significant values of pIC50 (> 5.26).
Conclusion: Combined approach of VS allowed us to select that aporphynic alkaloid xyloguyelline as potential multitarget compound for leishmanial treatment, presenting activity against five strategic enzymes to treatment with probability of activity over 60% by RF model.
Keywords: Alkaloids, Anaxagorea dolichocarpa, Virtual Screening, Molecular Docking, Random Forest, Leishmania donovani, antileishmania activity.
Current Pharmaceutical Design
Title:Structure- and Ligand-Based Approaches to Evaluate Aporphynic Alkaloids from Annonaceae as Multi-Target Agent Against Leishmania donovani
Volume: 22 Issue: 34
Author(s): Vitor Prates Lorenzo, Ana Silvia Suassuna Carneiro Lúcio, Luciana Scotti, Josean Fechine Tavares, José Maria Barbosa Filho, Tatjana Keesen de Souza Lima, Juliana da Câmara Rocha and Marcus Tullius Scotti
Affiliation:
Keywords: Alkaloids, Anaxagorea dolichocarpa, Virtual Screening, Molecular Docking, Random Forest, Leishmania donovani, antileishmania activity.
Abstract: Background: Leishmaniasis is a neglected disease that affects 15 million people around the world. Many limitations are associated to the treatment as high cost and toxicity. Several classes of natural substances with proven leishmanicidal activity were reported in the literature. Phytochemsitry study of Anaxagorea dolichocarpa (Annonacea) reported the isolation of aporphine alkaloids.
Methods: In this study, we evaluate the potential activity of the azaphenanthrene alkaloids eupolaramine, imbiline 1, imbiline 4, sampangine, 3-metoxisampangine and 4- metoxisampangine, isolated from A. dolichocarpa, together with a homemade databank of 142 aporphynic alkaloids isolated from Annonaceae, through ligand-based and structurebased virtual screening (VS) against Leishmania donovani. A diverse set selected from CHEMBL databank of 1397 structures, with tested antileishmanial activity against promastigote L. donovani, were classified according pIC50 values in order to generate and validate Random Forest model that show higher statistical indices values. The structure of six different L. donovani enzymes were downloaded from PDB databank and alkaloids structures were submitted to molecular docking.
Results: From the six azaphenanthrene alkaloids, sampangine, 3-methoxy, and 4-methoxy were indicated as potential actives by the RF model. Docking results gave similar values for all six azaphenanthrene alkaloids. So, we performed in vitro tests with sampangine, imbiline 1, imbiline 4, and eupolaramine, which are available in our laboratory, and that show significant values of pIC50 (> 5.26).
Conclusion: Combined approach of VS allowed us to select that aporphynic alkaloid xyloguyelline as potential multitarget compound for leishmanial treatment, presenting activity against five strategic enzymes to treatment with probability of activity over 60% by RF model.
Export Options
About this article
Cite this article as:
Lorenzo Prates Vitor, Lúcio Silvia Suassuna Carneiro Ana, Scotti Luciana, Tavares Fechine Josean, Filho Maria Barbosa José, Lima Keesen de Souza Tatjana, Rocha da Câmara Juliana and Scotti Tullius Marcus, Structure- and Ligand-Based Approaches to Evaluate Aporphynic Alkaloids from Annonaceae as Multi-Target Agent Against Leishmania donovani, Current Pharmaceutical Design 2016; 22 (34) . https://dx.doi.org/10.2174/1381612822666160513144853
DOI https://dx.doi.org/10.2174/1381612822666160513144853 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Extraction and Purification of Triterpenoids using Supercritical Fluids: From Lab to Exploitation
Mini-Reviews in Organic Chemistry Pregabalin in Neuropathic Pain: Evidences and Possible Mechanisms
Current Neuropharmacology Cytisine - From the Past to the Future
Current Pharmaceutical Design Stem Cell Research and Therapy for Liver Disease
Current Stem Cell Research & Therapy Vaccine Therapy of Melanoma: An Update
Current Cancer Therapy Reviews Anticancer Effects of Novel Tetrahydro-Dimethyl-Xanthene-Diones
Anti-Cancer Agents in Medicinal Chemistry Molecular Modeling and Ligand Docking for Solute Carrier (SLC) Transporters
Current Topics in Medicinal Chemistry Immunology of O-Glycosylated Proteins: Approaches to the Design of a MUC1 Glycopeptide-Based Tumor Vaccine
Current Protein & Peptide Science Recent Progress in Medicinal Investigations on Trichosanthin and other Ribosome Inactivating Proteins from the Plant Genus Trichosanthes
Current Medicinal Chemistry Multiple Functions of Mammalian Germinal Center Kinases
Current Chemical Biology N-Terminus Leader Sequence of Shiga Toxin (Stx) 1 Is Essential for Production of Active Recombinant Protein in E. coli
Protein & Peptide Letters Advanced Glycation End Products: Association with the Pathogenesis of Diseases and the Current Therapeutic Advances
Current Clinical Pharmacology Self-assembled Nucleic Acid Nanostructures for Cancer Theranostic Medicines
Current Topics in Medicinal Chemistry Editorial [Hot Topic: Nanotechnological and Biotechnological Strategies for Drug Delivery (Guest Editors: Massimiliano Galdiero and Michele Caraglia)]
Current Drug Metabolism Nucleic Acid Sensing Machinery: Targeting Innate Immune System for Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Benzodiazepine Metabolism: An Analytical Perspective
Current Drug Metabolism Anti-VEGF/VEGFR2 Monoclonal Antibodies and their Combinations with PD-1/PD-L1 Inhibitors in Clinic
Current Cancer Drug Targets High-Risk HPV/ErbB-2 Interaction on E-Cadherin/Catenin Regulation in Human Carcinogenesis
Current Pharmaceutical Design Selenite-induced Expression of a Caenorhabditis elegans Pro-aging Factor and Ortholog of Human Selenium-binding Protein 1
Current Nutraceuticals Cancer Immunotherapy: Battling Tumors with Gene Vaccines
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents